Literature DB >> 12846971

PET studies on the function of dopamine in health and Parkinson's disease.

David J Brooks1.   

Abstract

Positron emission tomography (PET) can detect the presence of striatal, pallidal, midbrain, and cortical dopamine terminal dysfunction in vivo in Parkinson's disease (PD). In addition, dopamine release during motor tasks can be assessed as reflected by changes in receptor availability to PET ligands. Furthermore, the functional effects of focal dopamine replacement via implantation of fetal cells or glia-derived neurotrophic factor (GDNF) infusion into putamen can be monitored. In this review, the insight that PET has given us concerning the role of dopamine in motor control is presented, and the functional substrates underlying PD symptomatologies are discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12846971     DOI： 10.1111/j.1749-6632.2003.tb07460.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


  5 in total

Review 1.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans.

Authors:  Kevin F Casey; Mariya V Cherkasova; Kevin Larcher; Alan C Evans; Glen B Baker; Alain Dagher; Chawki Benkelfat; Marco Leyton
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

3.  The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.

Authors:  Mitul A Mehta; Oliver D Howes; Alice Egerton; Arsime Demjaha; Philip McGuire
Journal:  Neuroimage       Date:  2009-12-23       Impact factor: 6.556

Review 4.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

Review 5.  6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses.

Authors:  M Pretze; C Wängler; B Wängler
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.